Cardiology Today

ARRHYTHMIA DISORDERS DU-176b equivalent to warfarin in non-valvular AF A once daily dose of DU-176b, a Factor Xa inhibitor, may be a safe alternative to treatment with warfarin in patients with atrial fibrillation, according to the results of a phase-2 study. “DU-176b is a promising new oral anticoagulant. When used at doses of 30 mg or 60 mg per day DU-176b appears to have a safety profile similar to that of warfarin,” said Jeffrey I. Weitz, MD, Henderson Research Centre, Hamilton, Ontario. Patients with non-valvular atrial fibrillation with a CHADS2 index >2 were enrolled in the study. Patients were assigned to warfarin or one ... FULL STORY

ARRHYTHMIA DISORDERS

DU-176b equivalent to warfarin in non-valvular AF

A once daily dose of DU-176b, a Factor Xa inhibitor, may be a safe alternative to treatment with warfarin in patients with atrial fibrillation, according to the results of a phase-2 study.

“DU-176b is a promising new oral anticoagulant. When used at doses of 30 mg or 60 mg per day DU-176b appears to have a safety profile similar to that of warfarin,” said Jeffrey I. Weitz, MD, Henderson Research Centre, Hamilton, Ontario.

Patients with non-valvular atrial fibrillation with a CHADS2 index >2 were enrolled in the study. Patients were assigned to warfarin or one ...
FULL STORY

October 18, 2009 6th International Meeting Intensive Cardiac Care Tel Aviv, Israel more information>>
October 4, 2009 11th International Workshop on Cardiac Arrhythmia Venice, Italy more information>>
June 21, 2009 EUROPACE Congress of the European Heart Rhythm Association Berlin, Germany more information>>

October 18, 2009
6th International Meeting Intensive Cardiac Care
Tel Aviv, Israel
more information>>

October 4, 2009
11th International Workshop on Cardiac Arrhythmia
Venice, Italy
more information>>

June 21, 2009
EUROPACE Congress of the European Heart Rhythm Association
Berlin, Germany
more information>>

See complete calendar listings. »

QUOTE OF THE WEEK "There was a significant milestone five years ago with the achievement of all the goals of the Human Genome Project...." Click here to read full article.

QUOTE OF THE WEEK

"There was a significant milestone five years ago with the achievement of all the goals of the Human Genome Project...."

Click here to read full article.

VASCULAR MEDICINE/INTERVENTION SCAI: Evidence of interaction between proton pump inhibitors, clopidogrel not sufficient to change practice Conflicting data from two studies of clopidogrel and proton pump inhibitors prompted one professional society to issue a statement clarifying the implications. According to a statement released by the Society for Cardiovascular Angiography and Interventions (SCAI), conflicting results from two studies presented at the American Heart Association Scientific Sessions 2008 in New Orleans raised questions about a potential interaction between clopidogrel (Plavix; Sanofi-Aventis, Bristol-Myers Squibb) and proton pump inhibitors in patients undergoing interventional procedures. The data were not suf... FULL STORY

VASCULAR MEDICINE/INTERVENTION

SCAI: Evidence of interaction between proton pump inhibitors, clopidogrel not sufficient to change practice

Conflicting data from two studies of clopidogrel and proton pump inhibitors prompted one professional society to issue a statement clarifying the implications. According to a statement released by the Society for Cardiovascular Angiography and Interventions (SCAI), conflicting results from two studies presented at the American Heart Association Scientific Sessions 2008 in New Orleans raised questions about a potential interaction between clopidogrel (Plavix; Sanofi-Aventis, Bristol-Myers Squibb) and proton pump inhibitors in patients undergoing interventional procedures. The data were not suf...

FULL STORY